|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Saitama Cancer Center Research
Institute, Saitama, Japan; The First Department of
Internal Medicine, Toho University School of Medicine, Tokyo,
Japan.
2'-Deoxycoformycin (dCF) as a single agent has been reported
to be less effective against myeloid than against lymphoid malignancies in clinical trials. However, previous studies have shown that in the
presence of 2'-deoxyadenosine (dAd), human monocytoid leukemia cell
lines are much more sensitive to dCF with regard to the inhibition of
cell proliferation. Thus, dCF might be useful for treating monocytoid
leukemia with the aid of dAd analogs. The antiproliferative effects of
dCF in combination with dAd or its derivatives were examined on normal
and malignant blood and bone marrow cells. In the presence of 10 µmol/L dAd, the concentration of dCF required to inhibit the
viability of primary monocytoid leukemia cells was much lower than that
required to inhibit normal or non-monocytoid leukemic cells. Among the
dAd analogs, 9- This article has been cited by other articles:
| |||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
-D-arabinofuranosyladenine (AraA) was
also effective in combination with dCF. Athymic nude mice were
inoculated with human monocytoid leukemia U937 cells and treated with
dCF or a dAd analog or both. Although dCF alone slightly but
significantly prolonged the survival of mice inoculated with U937
cells, combined treatment with dCF and AraA markedly prolonged
their survival. These data suggest that the combination of dCF and
AraA may be useful for the clinical treatment of acute monocytic leukemia.
